HCV E2区基因的分子克隆及序列分析

用RT－PCR KIT从西安血站大样抗HCV阳性血清中筛选出HCV RNA阳性血清,提取HCV的RNA,利用随机引物反转录合成其cDNA并进行半巢式PCR反应。将纯化的PCR产物酶切后与表达载体PET－22b^＋连接,经过双脱氧末端终止法双向测序,得到852bp长的核苷酸序列,通过将该序列与已知不同型的HCV E2序列比较得知,此序列正是HCVⅡ型目的基因。     

RT套式PCR检测血浆HCV RNA及与抗HCV检测的比较

应用微量血清热变性法提取核酸,逆转录套式聚合酶链反应(RT-nest PCR)检测血浆HCV RNA,并与抗HCV ELISA检测结果比较,对HCV RNA阳性标本进行HGV RNA的筛查.结果在32例抗HCV阳性和20例抗HCV阴性血浆中,HCV RNA分别检出18例和2例,总符合率为70%,20例HCV RNA阳性者中有2例合并感染HBV,1例合并感染HGV.证明血浆样本中抗HCV与HCV RNA间存在很大的相关性.     

肝癌细胞系（HepG2）感染HCV RNA的研究

为建立丙型肝炎病毒（HCV）体外感染和细胞培养系统,用定量的HCV RNA阳性血清感染人肝癌细胞系（HepG2细胞系）,应用地高辛标记HCV RNA探针原位杂交技术和RT－PCR方法对感染后的细胞和上清液听 HCV RNA进行了检测。在感染后的第一代至第七代的细胞中出现特异性杂交阳性信号,第一代、第二代和第六代检测出HCV RNA正链,并在感染后第一、二代检测出HCV RNA负链。显示HCV不仅能在体外感染HepG2细胞系,而且在基因的复制,证明HepG2细胞能作为HCV的体外细胞培育系。     

丙型肝炎病毒C区基因的克隆与分析

通过RT－PCR从1份来自甘肃武威地区献血员HCV阳性血清顺克隆到573bp的HCV核心基因全片段,用T－A克隆载体法将该片段接入克隆载体pUC19中并测序,结果表明武威地区分离株与Ⅰ型株HCV－Ⅰ和Ⅱ型株HCV－HeBei在该基因区段的核苷酸／氨基酸序列同源性分别为89.6%／95.4%、97.3%／97.4%,属于Ⅱ型株。     

可调控肝脏特异性表达HCV全基因转基因小鼠模型的建立

目的:构建一种可调控肝细胞特异性表达丙型肝炎病毒(HCV)全基因的小动物模型。方法:将9.6 kb的HCV全长基因JFH1插入Tet-on系统效应表达载体p TRE2中,并在HCV全基因3'端插入丁型肝炎病毒(HDV)核酶序列,从而构建转基因载体p TRE2-JFH1(HCV);将该转基因载体线性化后显微注射获得整合有HCV全基因的TRE2-HCV首建鼠;将该阳性鼠与本室保存的Alb-rt TA转基因小鼠杂交,获得肝细胞白蛋白启动子调控HCV全基因表达的Tet-on-Alb-HCV双转基因小鼠;在强力霉素(Dox)诱导后通过PCR、Western印迹、免疫组化等方法鉴定转基因小鼠HCV基因整合及HCV蛋白在肝组织中的表达;实时定量PCR检测小鼠血清及肝组织中的HCV滴度;用HCV反义小分子药物anti-mi R122评价该模型在药物评价中的应用。结果:获得了整合rt TA基因和HCV全长基因的双转基因小鼠;Dox诱导下,该转基因小鼠可在肝组织长期特异性表达HCV全长基因,小鼠血清中可检测到HCV的RNA;分子药物anti-mi R122可降低血清中的HCV滴度。结论:构建了可调控肝组织特异性表达HCV全基因的转基因小鼠模型,该小鼠模型可应用于HCV药物筛选和评价研究。     

HCV包膜蛋白E2的克隆、表达与检测

构建丙型肝炎HCV包膜蛋白糖蛋白的E2基因原核表达载体,获得大量重组HCVE2蛋白,进行E2蛋白的抗原性及潜在保护作用研究。通过RT-PCR从HCVRNA阳性血清标本中扩增出975bp(383～708)E2基因片段,PCR产物经EcoR I和Sall I双酶切后连接到经同样酶切的PET-41a原核表达载体上,转化到大肠杆菌BL21(DE3)菌株,经Amp筛选,得到阳性重组质粒PET41a-HCVE2菌株,并以IPTG诱导蛋白表达,SDS-PAGE鉴定,表达产物经固定化金属配体亲和层析纯化,用ELLSA方法检测生物学活性。结果表明,构建的HCVE2包膜蛋白基因片段原核表达质粒所表达产物主要以包涵体形式存在,表达的融合蛋白与HCV阳性血清具有较好的反应原性。以HCVE2融合蛋白检测患者阳性血清具有良好的抗原性,有望能提高HCV抗体检测试剂盒的检出率。     

HCV E2区基因在真核表达系统中的表达

以原核表达载体pET-E2为模板,用PCR的方法重新扩增出带有适于真核表达载体多克隆位点的E2基因,PCR产物经纯化并双酶切后与相同处理的真核表达载体pSecTag2/Hygro连接并转化大肠杆菌DH5α感受态细胞,重组表达载体在大量扩增并纯化后再转染COS7细胞,收集的培养上清经过Ni-柱纯化,用ELISA进行血清检测显示,6份HCV阳性血清中有4份检出有E2抗体,而5份HCV阴性血清也有一份检出有E2抗体。     

丙型肝炎病毒分片段抗体检测蛋白质芯片质控参比品的建立及质量验证

建立能同时检测丙型肝炎病毒(HCV)嵌合抗体、核心抗体和NS3、NS4、NS5抗体的蛋白质芯片质控参比品,对质控合格的芯片进行质量验证。用3种HCV EIA试剂分别检测从3家医院收集的丙型肝炎病毒感染患血清及其他非HCV感染患血清,从3种EIA试剂同时阴性或阳性的血样中挑取阳性和阴性血清,然后用RNA hyb PCR试剂进行检测,从中再选取部分样本用RIBA3．0进行检测,确定HCV分片段抗体检测蛋白质芯片质控参比品。经质检合格的芯片用中国药品生物制品检定所的HCV参比品进行检定。通过490例临床标本的检测对芯片的质量进行进一步的验证。从收集的240份丙型肝炎病毒感染患血清及其他非HCV感染患血清筛选出30份血样(15份阳性,15份阴性)作为HCV分片段抗体检测蛋白芯片质控参比品。中国药品生物制品检定所的80份HCV参比品检定结果表明,混合抗体阳性检出率为39／40,阴性符合率为40／40,总符合率为98．7％;核心抗体阳性检出率为27／40,阴性符合率为40／40;NS3抗体阳性检出率为26／40,阴性符合率为39／40;NS4抗体阳性检出率为19／40,阴性符合率为40／40;NS5抗体阳性检出率2／40,阴性符合率为40／40。490例临床标本的检测结果表明,对于194例HCV阳性标本,蛋白质芯片混合抗体与ELISA的符合率达99．5％,分片段抗体符合率达97．4％,两种方法检测结果不符的标本经RIBA试剂确认,蛋白质芯片与RIBA试剂的符合率高度一致。对于296例各种HCV抗体阴性标本,蛋白质芯片检测结果全部为阴性。以上结果表明,制备的丙型肝炎病毒分片段抗体检测蛋白质芯片质控参比品可用于芯片生产的质量控制,经质控合格的芯片符合国家标准的要求,可用于临床检测。     

吉林省延边地区丙型肝炎病毒基因型分布

为了解延边地区不同丙型肝炎病毒(HCV)基因型的分布特点,应用逆转录-聚合酶链反应(RT-PCR)技术,检测了48例本地区抗HCV阳性血清,结果有29例出现HCVRNA阳性.再利用限制性片段长度多态性(RFLP)技术,对29例RT-PCR阳性标本进行HCV基因分型.结果延边地区主要流行HCVⅡ型,其次是HCVⅢ型,也存在HCVⅡ/Ⅲ混合型,且HCVⅢ型的感染率较高.     

抗—HCV阴性献血员中丙型肝炎病毒RNA检测及序列分析

对95份抗—HCVIgG阴性献血员采用逆转录聚合酶链反应法（PCR）检测丙型肝炎病毒RNA,结果8次中有6次其检测出17份阳性标本（17／95,17．9％）,复查抗—HCVIgG仍为阴性。对其中8份阳性产物中高变区1的序列分析结果表明均为不同株HCV序列．排除了PCR污染的可能性。对其中2份阳性产物测定了全序列并与HCV各基因型代表株的相应序列比较,与HCVⅡ型相应序列的核苷酸同源性为77％～79％。而与HCVⅠ、Ⅲ、Ⅳ相应序列间的同源性为62％～69％,表明为HCVⅡ型序列。结果提示献血员抗—HCVIgG筛选不能完全排除HCV感染者,漏检不是由于HCV基因序列变异．而是检测方法本身缺陷所致。     

A ribonuclease protection assay for the direct detection and quantitation of hepatitis C virus RNA

A ribonuclease protection assay (RPA) was developed for the direct detection and quantitation of HCV RNA in infected patients' sera or plasma using HCV [(32)P]RNA from the conserved 5'-untranslated region (5'-UTR) as a probe. We were able to directly detect the presence of HCV RNA by RPA in several infected patients' samples. The viremic status of HCV infected patients with indeterminate recombinant immunoblot assay (RIBA II) was also determined by this assay. Polymerase chain reaction (PCR) was also performed on all these samples and were found to be positive with a concordance of 100% between the results of PCR and RPA. The RPA was able to detect approximately 1 pg of HCV RNA. A limited sequence heterogeneity among HCV isolates was also observed by this assay, suggesting that this may be a faster method of detecting heterogeneous HCV sequences in patients' samples. This simple and specific method could be used to quantitate HCV RNA in order to better determine viremia and follow the course of HCV infection especially when RIBA II results are indeterminate.     

我国非肠道传播非甲非乙型肝炎(丙型)病毒NS3蛋白的部份cDNA克隆及序列分析

用15ml非肠道传播非甲非乙型肝炎病人的混合血清提取病毒RNA,经逆转录和聚合酶链反应(PCR)扩增,获得583个核苷酸的非肠道传播非甲非乙型肝炎病毒(HCV)NS3蛋白的cDNA片段.该片段与美国报道的同片段HCV cDNA原型比较,核酸序列同源性为80.9％,氨基酸序列同源性为93.2％。与日本报道的同片段J1 HCV cDNA相比较,核酸序列和氨基酸序列的同源性分别为92.6％和95.2％。用α-~(32)P同位素标记该片段,与HCV病人血清出现杂交反应。     

我国猪瘟病毒兔化弱毒株囊膜糖蛋白E0基因的克隆及序列测定

采用异硫氰酸胍一步法从４８０代猪瘟病毒兔化弱毒株（ＨＣＬＶ）脾毒中提取总ＲＮＡ,以该ＲＮＡ为模板,进行反转录,然后采用套式ＰＣＲ扩增出ＨＣＬＶ的囊膜糖蛋白Ｅ０基因,琼脂糖凝胶电泳表明其大小与预计相符。将扩增出的Ｅ０基因克隆到ｐＧＥＭＴ载体中,用自动序列分析仪对其进行序列测定。将测得的序列及推导的氨基酸序列与国外测得的Ｃ株相应序列进行比较,结果发现,它们之间核苷酸序列同源性为９９．０８％,氨基酸序列同源性为９８．４２％。     

丙型肝炎病毒RNA打点杂交检测方法同RT－PCR方法的比较

采用ＨＣＶ基因组结构区Ｃ区ｃＤＮＡ探针和非结构区ＮＳ３－４区ｃＤＮＡ探针,建立了用打点杂交（ｄｏｔｂｌｏｔｈｙｂｒｉｄｉｚａｔｉｏｎ）检测血清中ＨＣＶＲＮＡ的方法,同采用ＨＣＶ基因组５’端非编码区的一对寡核苷酸引物通过逆转录－聚合酶链式反应（ＲＴ－ＰＣＲ）检测血清中ＨＣＶＲＮＡ的方法相比较,发现两种方法都能快速早期和特异地检出血清中ＨＣＶＲＮＡ,但ＲＴ－ＰＣＲ法敏感性优于ＲＮＡ打点杂交法。对于无血清学指标的慢性ＮＡＮＢ肝炎病人的诊断,可采用这两种方法。这两种方法的敏感性在很大程度上依赖于引物和探针的敏感性,以及ＲＮＡ提取方法。ＲＴ－ＰＣＲ法适用于诊断病毒血症和复制,打点杂交法适用于研究ＨＣＶＲＮＡ量的变化,对治疗的评价,以及为实验筛选较高滴度的ＨＣＶＲＮＡ阳性样本。     

Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C

Occult hepatitis C virus (HCV) infection of patients with abnormal liver function tests of unknown origin who are anti-HCV and serum HCV RNA negative but who have HCV RNA in the liver has been described. As HCV replicates in the liver cells of these patients, it could be that the amount of circulating viral particles is under the detection limit of the most sensitive techniques. To prove this hypothesis, serum samples from 106 patients with occult HCV infection were analyzed. Two milliliters of serum was ultracentrifuged over a 10% sucrose cushion for 17 h at 100,000 x g(av), where av means average, and HCV RNA detection was performed by strand-specific real-time PCR. Out of the 106 patients, 62 (58.5%) had detectable serum HCV RNA levels after ultracentrifugation, with a median load of 70.5 copies/ml (range, 18 to 192). Iodixanol density gradient studies revealed that HCV RNA was positive at densities of 1.03 to 1.04 and from 1.08 to 1.19 g/ml, which were very similar to those found in the sera of patients with classical chronic HCV infection. Antigenomic HCV RNA was found in the livers of 56 of 62 (90.3%) patients with detectable serum HCV RNA levels after ultracentrifugation, compared to 27 of 44 (61.4%) negative patients (P < 0.001). No differences in the median loads of antigenomic HCV RNA between patients with an those without serum HCV RNA (4.5 x 10(4) [range, 7.9 x 10(2) to 1.0 x 10(6)] versus 2.3 x 10(4) [range, 4.0 x 10(2) to 2.2 x 10(5)]) were found. Alanine aminotransferase and gamma-glutamyl transpeptidase levels, liver necroinflammatory activity, and fibrosis did not differ between both groups. In conclusion, HCV RNA can be detected in the sera of patients with occult HCV infection after circulating viral particles are concentrated by ultracentrifugation.     

Heterogeneity within the nonstructural protein 5-encoding region of hepatitis C viruses from a single patient.

Nucleotide (nt) sequence heterogeneity of the hepatitis C virus (HCV) genome derived from a single carrier was investigated. A polymerase chain reaction (PCR) product of 311 bp in the putative nonstructural protein 5-encoding region was directly sequenced, while part of a PCR product was cloned, and sequence analyses were carried out for 27 independent clones. Although 14 of the 27 clones were conserved, ten other types of nt sequences were found. The difference was at most 3 nt (1.1%). A directly determined sequence showed the major sequence of the cloned products. Since most of the nt changes occurred in the third letter of a codon, these nt changes might not have originated from random misincorporation during the PCR. These results of natural divergence of genome population in a single carrier suggest that HCV is a typical RNA virus with a quasi-species nature due to high mutation rates.     

Hepatitis C Virus Infection-Associated Markers in Sera from Blood Donors in Surabaya,Indonesia

Among 2,233 sera obtained from volunteer blood donors, 259 (11.6%) showed elevated alanine aminotransferase (ALT) levels. A second-generation enzyme-linked immunosorbent assay (ELISA) revealed that 23 (8.9%) of the 259 sera were positive for antibodies against hepatitis C virus (HCV), whereas only 9 (1.4%) of 646 sera randomly collected from blood donors with normal ALT levels were positive (P<0.001). The overall prevalence of anti-HCV antibodies among blood donors was estimated to be 2.3%. HCV RNA was detected in 19 (83%) of the 23 anti-HCV-positive sera with elevated ALT levels, and 8 (89%) of the 9 sera with normal ALT levels. Among the anti-HCV-positive sera, IgM anti-HCV was detected in 5 (22%) of 23 sera with elevated ALT levels and in 2 (22%) of 9 sera with normal ALT levels. All of the IgM anti-HCV-positive sera were positive for HCV RNA, irrespective of ALT levels.     

NASBA荧光分子信标技术定量检测丙型肝炎病毒

建立NASBA荧光分子信标探针检测技术,并对国家HCV标准品、人工构建HCVRNA野生株及HCV抗体阳性不同人群进行检测。实验结果:该方法检测HCV的灵敏度为103拷贝ml血清,阴性参比品的符合率为100%;检测的线性范围为103拷贝～109拷贝ml血清;精密性(CV值)小于6%,在HCV抗体阳性人群中HCVRNA的检出率在45%～65%之间。结论:该方法在HCVRNA临床定量检测中具有良好的灵敏度、特异性、重复性与实用性。     

Detection of hepatitis C virus RNA in alpha interferon derived from in vitro culture of leukocytes of human origin.

In order to assure the virological safety of blood products, in addition to serological testing of individual donations and virus inactivation steps undertaken during manufacture, routine PCR testing for HCV RNA of starting materials (plasma, cells), intermediates or final product is necessary. The aim of this study was to determine the rate of HCV RNA positive batches of human native leukocyte interferon during large-scale production. Our findings indicate the presence of HCV RNA in 6.1% batches despite acidification of intermediates in order to inactivate Sendai virus.